Literature DB >> 3781629

Pneumococcal intracellular killing is abolished by polysaccharide despite serum complement activity.

J E Schweinle.   

Abstract

Normal human serum absorbed at 0 degrees C with pneumococcal serotype 1, 12, or 25 lost the ability to support polymorphonuclear leukocyte intracellular killing of some pneumococcal serotypes even if immunoglobulin was provided. The absorbed serum contained no organisms but had residual polysaccharide when measured by counterimmunoelectrophoresis against type-specific antisera. The influence of pneumococcal polysaccharide (PPS) on serum support of intracellular polymorphonuclear leukocyte killing was evaluated. Normal human serum was mixed with PPS serotype 1, 12, or 25 at 0 degrees C for up to 120 min and then used as the opsonic source in standard phagocytic killing assays with serotype 1, 12, or 25. Immediately after mixing, each serum combined with PPS serotype 1, 12, or 25 supported killing of all serotypes tested. With increasing time at 0 degrees C with serotype 1 PPS, serum exhibited a marked progressive decline in killing of serotype 25, a similar but less marked impairment in killing of serotype 12, and essentially no impairment for serotype 1. Serum treated with type 25 PPS did not support killing of type 25, but allowed normal killing of types 1 and 12. Incubation with type 12 PPS impaired opsonization of types 12 and 25, but not 1. Addition of PPS-specific antisera did not restore killing. Residual serum hemolytic activity of classic and alternative complement pathways was not reduced below opsonizing levels after 120 min at 0 degrees C. Furthermore, PPS treatment of normal human serum did not alter the attachment or ingestion of 14C-labeled pneumococci by polymorphonuclear leukocytes. Some serotypes of PPS reacted slowly with serum at 0 degrees C, diminishing its ability to support intracellular killing of pneumococci despite serum hemolytic complement activity. Phagocytosis was not inhibited. Specific antibody did not overcome inactivation. Different requirements for the inactivated factor among serotypes may be a characteristic related to organism virulence.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3781629      PMCID: PMC260252          DOI: 10.1128/iai.54.3.876-881.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  Prevention of pneumococcal pneumonia by vaccination.

Authors:  R Austrian; R M Douglas; G Schiffman; A M Coetzee; H J Koornhof; S Hayden-Smith; R D Reid
Journal:  Trans Assoc Am Physicians       Date:  1976

2.  Emergence of multiply resistant pneumococci.

Authors:  M R Jacobs; H J Koornhof; R M Robins-Browne; C M Stevenson; Z A Vermaak; I Freiman; G B Miller; M A Witcomb; M Isaäcson; J I Ward; R Austrian
Journal:  N Engl J Med       Date:  1978-10-05       Impact factor: 91.245

3.  Failure of pneumococcal vaccine in children with sickle-cell disease.

Authors:  V I Ahonkhai; S H Landesman; S M Fikrig; E A Schmalzer; A K Brown; C E Cherubin; G Schiffman
Journal:  N Engl J Med       Date:  1979-07-05       Impact factor: 91.245

4.  Evidence for quantitative variability of bacterial opsonic requirements.

Authors:  J C Guckian; W D Christensen; D P Fine
Journal:  Infect Immun       Date:  1978-03       Impact factor: 3.441

5.  Enhancing role of IgG in lysis of rabbit erythrocytes by the alternative pathway of human complement.

Authors:  B Nelson; S Ruddy
Journal:  J Immunol       Date:  1979-05       Impact factor: 5.422

6.  Possible pathogenetic role of capsular antigens in fulminant pneumococcal disease with disseminated intravascular coagulation (DIC).

Authors:  M W Rytel; T H Dee; J E Ferstenfeld; G T Hensley
Journal:  Am J Med       Date:  1974-12       Impact factor: 4.965

7.  Requirement of extracellular complement and immunoglobulin for intracellular killing of micro-organisms by human monocytes.

Authors:  P C Leijh; M T van den Barselaar; T L van Zwet; M R Daha; R van Furth
Journal:  J Clin Invest       Date:  1979-04       Impact factor: 14.808

8.  Immunologic studies in pneumococcal disease.

Authors:  T H Dee; G Schiffman; M I Sottile; M W Rytel
Journal:  J Lab Clin Med       Date:  1977-06

9.  Serum opsonic deficiency produced by Streptococcus pneumoniae and by capsular polysaccharide antigens.

Authors:  G S Giebink; J V Grebner; Y Kim; P G Quie
Journal:  Yale J Biol Med       Date:  1978 Sep-Oct

10.  The properdin system and immunity. III. The zymosan assay of properdin.

Authors:  L PILLEMER; L BLUM; I H LEPOW; L WURZ; E W TODD
Journal:  J Exp Med       Date:  1956-01-01       Impact factor: 14.307

View more
  2 in total

Review 1.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

Review 2.  Recent approaches in whole cell pneumococcal vaccine development: a review study.

Authors:  Mona Mohammadzadeh; Setareh Mamishi; Babak Pourakbari; Shima Mahmoudi
Journal:  Iran J Microbiol       Date:  2017-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.